ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2014
Lupus nephritis: the evolving role of novel therapeutics.
Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Immunosuppressive treatment for proliferative lupus nephritis.The Cochrane database of systematic reviews · 2018Pooled it
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2016Trial
- Taming renal inflammation: signaling pathways and therapeutic advances in lupus nephritis.BMC nephrology · 2025Review
- Patterns of Glomerular Injury: Histopathological Classification and Clinical Correlation.Cureus · 2025Review
- Urinary MCP-1 and VCAM-1 as non-invasive biomarkers for the diagnosis and activity assessment of lupus nephritis.PloS one · 2025Article
- Podocyte, tubular epithelial-immune cell interplay in the pathogenesis of lupus nephritis.Frontiers in immunology · 2025Review
- Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.Kidney international · 2024Review
- Unveiling the Hidden Power of Uromodulin: A Promising Potential Biomarker for Kidney Diseases.Diagnostics (Basel, Switzerland) · 2023Review
- Spatial proteomics landscape and immune signature analysis of renal sample of lupus nephritis based on laser-captured microsection.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Anti-inflammatory effect of dental pulp stem cells.Frontiers in immunology · 2023Review
- HSPB5 suppresses renal inflammation and protects lupus-prone NZB/W F1 mice from severe renal damage.Arthritis research & therapy · 2022Article
- The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.Nature reviews. Nephrology · 2022Review
- Article
- A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis.Frontiers in immunology · 2021Article
- Iron Metabolism: An Under Investigated Driver of Renal Pathology in Lupus Nephritis.Frontiers in medicine · 2021Review
- Quantifying the effects of biopsy fixation and staining panel design on automatic instance segmentation of immune cells in human lupus nephritis.Journal of biomedical optics · 2021Article
- Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases.Nature reviews. Rheumatology · 2020Review
- Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus.Frontiers in immunology · 2020Article
- ALW peptide ameliorates lupus nephritis in MRL/lpr mice.Arthritis research & therapy · 2019Article
- The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.BMC nephrology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in kidney inflammation and injury. Cytotoxic agents and corticosteroids are standard of care for lupus nephritis treatment, but are associated with considerable morbidity and suboptimal outcomes. Recently, there has been interest in using novel biologic agents and small molecules to treat lupus nephritis. These therapies can be broadly categorized as anti-inflammatory (laquinamod, anti-tumor necrosis factor-like weak inducer of apotosis, anti-C5, and retinoids), antiautoimmunity (anti-CD20, anti-interferon α, and costimulatory blockers), or both (anti-interleukin 6 and proteasome inhibitors). Recent lupus nephritis clinical trials applied biologics or small molecules of any category to induction treatment, seeking short-term end points of complete renal response. These trials in general have not succeeded. When lupus nephritis comes to clinical attention during the inflammatory stage of the disease, the autoimmune stage leading to kidney inflammation will have been active for some time. The optimal approach for using novel therapies may be to initially target kidney inflammation to preserve renal parenchyma, followed by suppression of autoimmunity. In this review, we discuss novel lupus nephritis therapies and how they fit into a combinatorial treatment strategy based on the pathogenic stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.